Genital Herpes

[Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination]. – PubMed


Groups of subjects during acute (0-3 days) and convalescent (2-3 weeks) phase of recurrent herpes labialis (RHL), and other subjects seropositive or seronegative for herpes simplex virus type 1 (HSV-1) antibody without any history of RHL, were tested for the appearance of cell-mediated cytotoxic responses by stimulating peripheral blood leukocytes (PBL) in vitro with ultraviolet-inactivated HSV-1 antigen, using the release of radiolabelled chromium (51Cr) from HSV-1-infected autologous, or allogeneic lymphocytes and K562 erythroleukemia cell line as nonspecific targets. Our investigations add further support for this notion. Virus has been isolated from the minority of corneas cultured, whereas viral particles have been demonstrated in selected cases of stromal keratitis, most of which had been treated with steroids at some point in time. Co-administration of MLI, MLII or MLIII with gD2 led to significantly higher levels of gD2-specific mucosal immunoglobulin A (IgA) and systemic immunoglobulin G (IgG) antibody than when the antigen was delivered alone. Oral and genital mucosal secretions were sampled and tested for the presence of infectious HSV and HSV DNA. After vaccination all patients remained herpes-free for at least 4-6 months. In a separate study a follow-up up to 10 years was done.

injection 7 days before subcutaneous immunization. Although the contribution of humoral immune response is controversial, CD4+ Th1 T cells producing IFN-γ are believed to play an important role in eradicating virus from the hosts. Links to PubMed are also available for Selected References. Since the BCG vaccination can be assumed to be virtually without risk, a Tine-test followed by BCG vaccination should be considered as treatment of choice in patients with recurrent HS for prevention of recurrences.